Updated:
Seqens SAS
Seqens SAS is a French CDMO providing integrated drug substance and drug product manufacturing for pharmaceutical and biotech clients globally.
Seqens SAS
Seqens SAS was established as a chemical manufacturing company that grew through acquisitions and organic expansion into a leading European CDMO. The firm's roots trace to the former PCAS group, which it rebranded as Seqens in 2017. The company's strategy centers on integrated CDMO services across both small molecules and biologicals. Seqens operates manufacturing facilities in France and the United States, producing active pharmaceutical ingredients (APIs), high-potency compounds, and controlled-release excipients. Their service model spans pre-clinical development through commercial-scale production, targeting pharmaceutical and biotechnology companies globally. Seqens employs over 1,500 professionals across sites including Lyon, France, and Mirabel, Quebec, Canada. The firm has no publicly disclosed AUM or direct investment operations; it is an operating company in the biochemical sector, not an asset manager. Recent activity includes the 2023 acquisition of a Canadian sterile injectables facility from Mylan (per the company's press releases). Seqens' structural differentiator is its fully integrated drug substance-to-drug product capability under a single company, reducing supply-chain complexity for pharmaceutical clients. This vertical integration — from early R&D to commercial-scale sterile manufacturing — positions it distinctly among European CDMOs, though it does not operate as an investment vehicle or family office.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
France
City
Lyon
Corporate office
Lyon, France
Sector focus
Frequently asked questions
What services does Seqens provide to pharmaceutical clients?
Seqens offers contract development and manufacturing (CDMO) services for active pharmaceutical ingredients (APIs), including high-potency compounds, advanced intermediates, and controlled-release excipients, as well as sterile injectable drug product manufacturing. They support clients from pre-clinical development through commercial production (public record).
Does Seqens operate as a family office, asset manager, or investment firm?
No. Seqens is an industrial company — a contract manufacturer for the pharmaceutical and life sciences industries. It does not manage third-party capital or operate a family office structure. The firm is best understood as a specialty chemical and pharmaceutical manufacturing group.
Who owns Seqens?
Seqens is privately held through a holding company structure. Current ownership details are not publicly disclosed. The company's history includes backing by private equity investors, but no current named principal is publicly available.
Where are Seqens' manufacturing facilities located?
Seqens operates manufacturing sites in Lyon, France; Quebec, Canada; and additional locations in the United States. The Quebec facility, acquired in 2023, focuses on sterile injectable production (public record).
What is the scale of Seqens' workforce and operations?
The company employs over 1,500 people globally. It operates multiple cGMP-compliant facilities serving pharmaceutical and biotechnology customers across the drug development lifecycle (public record).
Is Seqens publicly traded?
No. Seqens is a private company. It does not have publicly traded shares or publicly disclosed financial statements. The firm's revenues and profitability are not published.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: